MilliporeSigma will invest €35 million ($37 million) in biosafety testing at its Stirling and Glasgow sites in Scotland. MilliporeSigma – the life sciences division of Germany’s Merck KGaA – will invest the funds into a 1,200 square meter facility in Glasgow. The life sciences firm said the plant will have molecular biology and sequencing services, as well as increasing the testing capacity its current space with biosafety testing, viral clearance suites, and analytical development. Biosafety testing ensures that drugs are safe, efficacious,…